Dynavax Technologies Key Executives
This section highlights Dynavax Technologies's key executives, including their titles and compensation details.
Find Contacts at Dynavax Technologies
(Showing 0 of )
Dynavax Technologies Earnings
This section highlights Dynavax Technologies's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-20 | $0.05 | $0.05 |
| Read Transcript | Q3 | 2024 | 2024-11-07 | $0.11 | $0.12 |
| Read Transcript | Q2 | 2024 | 2024-08-06 | $0.06 | $0.08 |
| Read Transcript | Q1 | 2024 | 2024-05-08 | $-0.05 | $-0.07 |
| Read Transcript | Q4 | 2023 | 2024-02-22 | $0.00 | $0.00 |
| Read Transcript | Q3 | 2023 | 2023-11-02 | $0.01 | $0.10 |
| Read Transcript | Q2 | 2023 | 2023-08-03 | $-0.09 | $0.03 |
| Read Transcript | Q1 | 2023 | 2023-05-02 | $-0.12 | $-0.19 |
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
$11.27
Stock Price
$1.38B
Market Cap
405
Employees
EmeryVille, CA
Location
Financial Statements
Access annual & quarterly financial statements for Dynavax Technologies, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $277.25M | $232.28M | $722.68M | $439.44M | $46.55M |
| Cost of Revenue | $- | $50.17M | $262.15M | $173.57M | $13.91M |
| Gross Profit | $277.25M | $182.12M | $460.53M | $265.87M | $32.64M |
| Gross Profit Ratio | 100.00% | 78.40% | 63.73% | 60.50% | 70.12% |
| Research and Development Expenses | $61.55M | $54.89M | $46.60M | $32.23M | $28.61M |
| General and Administrative Expenses | $170.37M | $152.95M | $131.41M | $100.16M | $79.26M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $24.76M |
| Selling General and Administrative Expenses | $170.37M | $152.95M | $131.41M | $100.16M | $79.26M |
| Other Expenses | $49.45M | $11.31M | $7.80M | $8.66M | $6.81M |
| Operating Expenses | $281.37M | $219.15M | $178.01M | $132.38M | $107.86M |
| Cost and Expenses | $281.37M | $269.31M | $440.16M | $305.96M | $121.77M |
| Interest Income | $36.46M | $31.99M | $7.91M | $140.00K | $1.26M |
| Interest Expense | $6.79M | $6.76M | $6.73M | $11.18M | $19.06M |
| Depreciation and Amortization | $8.05M | $7.28M | $6.67M | $7.01M | $9.34M |
| EBITDA | $45.70M | $9.67M | $307.70M | $95.71M | $-46.84M |
| EBITDA Ratio | 16.48% | 4.16% | 42.58% | 21.78% | -100.63% |
| Operating Income | $-4.12M | $-37.03M | $283.52M | $134.49M | $-75.22M |
| Operating Income Ratio | -1.49% | -15.94% | 39.23% | 30.60% | -161.59% |
| Total Other Income Expenses Net | $34.98M | $32.66M | $10.78M | $-56.97M | $-6.87M |
| Income Before Tax | $30.86M | $-4.37M | $294.30M | $77.52M | $-75.24M |
| Income Before Tax Ratio | 11.13% | -1.88% | 40.72% | 17.64% | -161.63% |
| Income Tax Expense | $3.55M | $2.02M | $1.14M | $808.00K | $16.54M |
| Net Income | $27.31M | $-6.39M | $293.16M | $76.71M | $-91.78M |
| Net Income Ratio | 9.85% | -2.75% | 40.56% | 17.46% | -197.15% |
| EPS | $0.21 | $-0.05 | $2.32 | $0.62 | $-0.91 |
| EPS Diluted | $0.20 | $-0.05 | $1.97 | $0.54 | $-0.91 |
| Weighted Average Shares Outstanding | 130.05M | 128.73M | 126.40M | 116.26M | 100.75M |
| Weighted Average Shares Outstanding Diluted | 133.34M | 128.73M | 150.80M | 133.01M | 100.75M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.03M | $80.63M | $73.80M | $50.79M | $55.60M | $69.51M | $60.25M | $46.92M | $184.49M | $167.74M | $256.46M | $113.99M | $195.07M | $108.27M | $52.77M | $83.33M | $19.55M | $13.41M | $2.67M | $10.92M |
| Cost of Revenue | $13.41M | $13.08M | $11.98M | $10.97M | $8.69M | $13.23M | $13.54M | $14.71M | $77.49M | $61.33M | $83.37M | $39.96M | $74.01M | $60.09M | $14.85M | $24.62M | $4.06M | $4.03M | $1.17M | $4.65M |
| Gross Profit | $58.62M | $67.55M | $61.81M | $39.82M | $46.91M | $56.28M | $46.71M | $32.21M | $107.00M | $106.40M | $173.09M | $74.03M | $121.06M | $48.18M | $37.92M | $58.71M | $15.49M | $9.38M | $1.50M | $6.27M |
| Gross Profit Ratio | 81.38% | 83.77% | 83.76% | 78.41% | 84.37% | 80.97% | 77.53% | 68.65% | 58.00% | 63.43% | 67.49% | 64.94% | 62.06% | 44.50% | 71.87% | 70.45% | 79.24% | 69.95% | 56.18% | 57.40% |
| Research and Development Expenses | $18.67M | $14.40M | $14.95M | $13.53M | $14.12M | $14.12M | $13.05M | $13.61M | $12.85M | $12.96M | $9.69M | $11.10M | $11.12M | $6.19M | $7.17M | $7.76M | $9.55M | $8.52M | $5.88M | $4.65M |
| General and Administrative Expenses | $41.59M | $43.06M | $41.66M | $44.06M | $41.28M | $38.05M | $37.07M | $36.54M | $31.02M | $32.04M | $36.18M | $32.17M | $29.22M | $26.93M | $21.58M | $22.42M | $17.84M | $21.54M | $18.95M | $20.93M |
| Selling and Marketing Expenses | $- | $- | $-862.00K | $-1.19M | $-70.39M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $4.85M | $7.70M | $5.58M | $6.62M |
| Selling General and Administrative Expenses | $41.59M | $43.06M | $40.80M | $42.88M | $41.28M | $38.05M | $37.07M | $36.54M | $31.02M | $32.04M | $36.18M | $32.17M | $29.22M | $26.93M | $21.58M | $22.42M | $17.84M | $21.54M | $18.95M | $20.93M |
| Other Expenses | $- | $- | $2.21M | $-1.50M | $1.62M | $2.26M | $1.92M | $1.62M | $2.20M | $1.82M | $2.06M | $1.71M | $2.32M | $2.26M | $1.50M | $2.58M | $1.24M | $1.51M | $1.82M | $2.25M |
| Operating Expenses | $60.25M | $57.46M | $55.75M | $56.40M | $55.40M | $52.17M | $50.12M | $50.15M | $43.87M | $45.00M | $45.87M | $43.27M | $40.34M | $33.11M | $28.75M | $30.18M | $27.39M | $30.06M | $24.84M | $25.58M |
| Cost and Expenses | $73.66M | $70.55M | $67.73M | $67.37M | $64.09M | $65.40M | $63.65M | $64.86M | $121.36M | $106.34M | $129.24M | $83.23M | $114.35M | $93.20M | $43.59M | $54.81M | $31.45M | $34.09M | $26.01M | $30.23M |
| Interest Income | $8.41M | $9.38M | $9.20M | $9.47M | $9.56M | $8.46M | $7.38M | $6.60M | $4.32M | $2.56M | $765.00K | $261.00K | $6.00K | $39.00K | $48.00K | $47.00K | $70.00K | $269.00K | $331.00K | $590.00K |
| Interest Expense | $1.70M | $1.41M | $1.41M | $1.41M | $2.53M | $1.69M | $1.41M | $1.69M | $1.68M | $1.69M | $1.68M | $1.68M | $1.68M | $1.68M | $3.11M | $4.71M | $4.80M | $4.79M | $4.73M | $4.73M |
| Depreciation and Amortization | $2.07M | $2.05M | $1.98M | $1.95M | $1.96M | $1.87M | $1.79M | $1.66M | $1.45M | $1.49M | $2.00M | $1.73M | $1.72M | $1.76M | $1.77M | $1.76M | $1.76M | $1.75M | $1.88M | $3.95M |
| EBITDA | $12.27M | $10.08M | $18.58M | $-7.85M | $4.65M | $17.71M | $7.69M | $-20.38M | $71.11M | $67.27M | $133.06M | $36.27M | $103.98M | $-24.99M | $9.35M | $7.36M | $-8.90M | $10.94M | $-44.97M | $-3.92M |
| EBITDA Ratio | 17.03% | 12.50% | 25.18% | -15.46% | 8.36% | 25.47% | 12.76% | -43.42% | 38.54% | 40.10% | 51.88% | 31.82% | 53.31% | -23.08% | 17.72% | 8.83% | -45.52% | 81.58% | -1685.49% | -35.88% |
| Operating Income | $-1.63M | $10.08M | $6.06M | $-16.58M | $-8.49M | $5.12M | $-3.40M | $-17.93M | $63.13M | $61.40M | $128.23M | $30.76M | $80.72M | $16.07M | $9.17M | $28.53M | $-11.89M | $-13.82M | $-23.34M | $-19.31M |
| Operating Income Ratio | -2.27% | 12.50% | 8.21% | -32.64% | -15.27% | 7.36% | -5.65% | -38.22% | 34.22% | 36.60% | 50.00% | 26.99% | 41.38% | 14.84% | 17.38% | 34.23% | -60.84% | -103.06% | -874.78% | -176.87% |
| Total Other Income Expenses Net | $9.26M | $9.74M | $8.85M | $5.08M | $9.49M | $9.03M | $7.61M | $6.53M | $4.84M | $2.69M | $1.15M | $2.10M | $19.87M | $-44.50M | $-4.70M | $-27.64M | $-3.57M | $18.23M | $-28.24M | $6.72M |
| Income Before Tax | $7.63M | $19.82M | $14.91M | $-11.50M | $996.00K | $14.15M | $4.21M | $-23.72M | $67.97M | $64.09M | $129.37M | $32.86M | $100.59M | $-28.43M | $4.47M | $891.00K | $-15.47M | $4.40M | $-51.58M | $-12.60M |
| Income Before Tax Ratio | 10.59% | 24.58% | 20.20% | -22.64% | 1.79% | 20.35% | 6.98% | -50.54% | 36.84% | 38.21% | 50.45% | 28.83% | 51.56% | -26.26% | 8.48% | 1.07% | -79.12% | 32.81% | -1933.25% | -115.35% |
| Income Tax Expense | $579.00K | $2.22M | $3.52M | $-2.78M | $777.00K | $-147.00K | $776.00K | $616.00K | $241.00K | $283.00K | $619.00K | $3.39M | $808.00K | $3.94M | $4.61M | $7.29M | $4.28M | $6.30M | $6.55M | $6.98M |
| Net Income | $7.05M | $17.59M | $11.39M | $-8.72M | $219.00K | $14.29M | $3.43M | $-24.33M | $67.73M | $63.81M | $128.75M | $32.73M | $99.78M | $-28.43M | $4.14M | $821.00K | $-15.47M | $4.40M | $-51.58M | $-12.60M |
| Net Income Ratio | 9.79% | 21.82% | 15.43% | -17.17% | 0.39% | 20.56% | 5.69% | -51.85% | 36.71% | 38.04% | 50.20% | 28.71% | 51.15% | -26.26% | 7.85% | 0.99% | -79.12% | 32.81% | -1933.25% | -115.35% |
| EPS | $0.06 | $0.13 | $0.09 | $-0.07 | $0.00 | $0.11 | $0.03 | $-0.19 | $0.53 | $0.42 | $0.86 | $0.22 | $0.80 | $-0.24 | $0.04 | $0.01 | $-0.14 | $0.04 | $-0.53 | $-0.15 |
| EPS Diluted | $0.05 | $0.11 | $0.08 | $-0.07 | $0.00 | $0.09 | $0.03 | $-0.19 | $0.45 | $0.42 | $0.86 | $0.22 | $0.55 | $-0.24 | $0.02 | $0.01 | $-0.14 | $0.04 | $-0.53 | $-0.15 |
| Weighted Average Shares Outstanding | 127.95M | 131.13M | 130.92M | 130.20M | 129.38M | 128.99M | 128.62M | 127.92M | 127.59M | 151.54M | 149.91M | 149.43M | 121.44M | 116.90M | 114.63M | 112.03M | 110.25M | 109.82M | 97.34M | 85.48M |
| Weighted Average Shares Outstanding Diluted | 153.02M | 154.81M | 154.47M | 130.20M | 133.28M | 154.20M | 128.62M | 127.92M | 151.73M | 151.54M | 149.91M | 149.43M | 188.40M | 116.90M | 118.83M | 113.47M | 110.28M | 111.97M | 97.34M | 85.65M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $95.88M | $150.28M | $202.00M | $436.19M | $32.07M |
| Short Term Investments | $617.95M | $592.02M | $422.39M | $109.76M | $132.96M |
| Cash and Short Term Investments | $713.83M | $742.30M | $624.39M | $545.95M | $165.04M |
| Net Receivables | $46.91M | $44.53M | $147.51M | $131.82M | $22.66M |
| Inventory | $70.05M | $53.29M | $59.45M | $61.34M | $63.69M |
| Other Current Assets | $18.15M | $19.00M | $85.63M | $233.42M | $38.63M |
| Total Current Assets | $848.94M | $859.12M | $683.84M | $607.28M | $228.72M |
| Property Plant Equipment Net | $60.61M | $61.58M | $63.34M | $60.98M | $57.15M |
| Goodwill | $1.95M | $2.07M | $2.01M | $2.12M | $2.30M |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $1.95M | $2.07M | $2.01M | $2.12M | $2.30M |
| Long Term Investments | $- | $- | $207.00K | $219.00K | $237.00K |
| Tax Assets | $- | $- | $-207.00K | $-219.00K | $-237.00K |
| Other Non-Current Assets | $74.76M | $74.33M | $236.66M | $368.85M | $65.10M |
| Total Non-Current Assets | $137.31M | $137.98M | $302.01M | $431.96M | $124.55M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $986.26M | $997.10M | $985.85M | $1.04B | $353.27M |
| Account Payables | $9.06M | $5.25M | $3.21M | $2.60M | $3.31M |
| Short Term Debt | $- | $4.50M | $3.63M | $2.58M | $3.25M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $349.86M | $38.21M |
| Other Current Liabilities | $69.57M | $52.45M | $143.23M | $201.36M | $32.64M |
| Total Current Liabilities | $78.63M | $62.20M | $150.07M | $556.40M | $77.41M |
| Long Term Debt | $250.24M | $252.42M | $254.38M | $254.81M | $214.60M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $60.58M | $60.41M | $384.00K | $5.66M | $2.57M |
| Total Non-Current Liabilities | $310.82M | $312.83M | $254.76M | $260.47M | $217.17M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $389.46M | $375.02M | $404.84M | $816.87M | $294.58M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $125.00K | $130.00K | $128.00K | $123.00K | $110.00K |
| Retained Earnings | $-903.27M | $-930.58M | $-924.20M | $-1.22B | $-1.29B |
| Accumulated Other Comprehensive Income Loss | $-4.72M | $-2.11M | $-5.44M | $-2.27M | $273.00K |
| Other Total Stockholders Equity | $1.50B | $1.55B | $1.51B | $1.44B | $1.35B |
| Total Stockholders Equity | $596.80M | $622.07M | $581.01M | $222.37M | $58.69M |
| Total Equity | $596.80M | $622.07M | $581.01M | $222.37M | $58.69M |
| Total Liabilities and Stockholders Equity | $986.26M | $997.10M | $985.85M | $1.04B | $353.27M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $986.26M | $997.10M | $985.85M | $1.04B | $353.27M |
| Total Investments | $617.95M | $592.02M | $422.39M | $109.76M | $132.96M |
| Total Debt | $250.24M | $256.91M | $258.01M | $257.38M | $217.85M |
| Net Debt | $154.36M | $106.64M | $56.01M | $-178.81M | $185.77M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $95.88M | $119.33M | $112.50M | $132.03M | $150.28M | $154.51M | $226.82M | $174.35M | $202.00M | $198.58M | $249.09M | $179.42M | $436.19M | $246.35M | $129.61M | $79.06M | $32.07M | $32.69M | $60.48M | $37.90M |
| Short Term Investments | $617.95M | $644.66M | $623.11M | $591.50M | $592.02M | $565.90M | $454.70M | $477.61M | $422.39M | $387.91M | $269.08M | $323.80M | $109.76M | $167.80M | $216.20M | $153.62M | $132.96M | $144.47M | $140.22M | $91.63M |
| Cash and Short Term Investments | $713.83M | $763.99M | $735.61M | $723.54M | $742.30M | $720.42M | $681.52M | $651.96M | $624.39M | $586.49M | $518.17M | $503.22M | $545.95M | $414.15M | $345.80M | $232.67M | $165.04M | $177.16M | $200.71M | $129.53M |
| Net Receivables | $46.91M | $75.28M | $62.63M | $46.15M | $44.53M | $46.87M | $45.35M | $104.87M | $147.51M | $131.12M | $174.24M | $136.94M | $131.82M | $200.36M | $105.90M | $83.99M | $22.66M | $35.02M | $903.00K | $8.13M |
| Inventory | $70.05M | $62.40M | $62.46M | $61.81M | $53.29M | $49.41M | $53.09M | $57.69M | $59.45M | $102.61M | $73.98M | $79.04M | $61.34M | $67.30M | $86.45M | $68.85M | $63.69M | $59.03M | $54.39M | $48.10M |
| Other Current Assets | $18.15M | $24.57M | $21.31M | $19.79M | $19.00M | $18.97M | $17.49M | $15.63M | $85.63M | $112.73M | $189.01M | $221.32M | $233.42M | $170.86M | $45.75M | $42.02M | $38.63M | $37.57M | $18.93M | $16.76M |
| Total Current Assets | $848.94M | $926.24M | $882.01M | $851.29M | $859.12M | $835.67M | $797.46M | $830.14M | $683.84M | $932.94M | $955.40M | $940.51M | $607.28M | $852.67M | $583.91M | $427.53M | $228.72M | $290.00M | $265.47M | $194.15M |
| Property Plant Equipment Net | $60.61M | $59.20M | $58.63M | $59.80M | $61.58M | $61.13M | $62.81M | $63.59M | $63.34M | $61.03M | $62.07M | $62.72M | $60.98M | $61.02M | $57.71M | $56.49M | $57.15M | $57.73M | $58.35M | $59.33M |
| Goodwill | $1.95M | $2.09M | $2.01M | $2.02M | $2.07M | $1.98M | $2.04M | $2.04M | $2.01M | $1.83M | $1.96M | $2.08M | $2.12M | $2.17M | $2.23M | $2.20M | $2.30M | $2.20M | $2.10M | $2.06M |
| Intangible Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $202.00K |
| Goodwill and Intangible Assets | $1.95M | $2.09M | $2.01M | $2.02M | $2.07M | $1.98M | $2.04M | $2.04M | $2.01M | $1.83M | $1.96M | $2.08M | $2.12M | $2.17M | $2.23M | $2.20M | $2.30M | $2.20M | $2.10M | $2.26M |
| Long Term Investments | $- | $- | $270.00K | $271.00K | $277.00K | $266.00K | $210.00K | $210.00K | $207.00K | $189.00K | $202.00K | $214.00K | $219.00K | $224.00K | $229.00K | $226.00K | $132.96M | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $-277.00K | $-266.00K | $-210.00K | $-210.00K | $-207.00K | $-189.00K | $-202.00K | $-214.00K | $-219.00K | $-224.00K | $-229.00K | $-226.00K | $-132.96M | $- | $- | $- |
| Other Non-Current Assets | $74.76M | $74.46M | $73.40M | $73.18M | $74.33M | $74.15M | $74.12M | $74.15M | $236.66M | $3.53M | $3.56M | $3.66M | $368.85M | $3.85M | $4.07M | $3.89M | $65.10M | $3.46M | $3.40M | $3.51M |
| Total Non-Current Assets | $137.31M | $135.75M | $134.31M | $135.28M | $137.98M | $137.27M | $138.97M | $139.78M | $302.01M | $66.39M | $67.59M | $68.46M | $431.96M | $67.04M | $64.00M | $62.59M | $124.55M | $63.39M | $63.85M | $65.11M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $986.26M | $1.06B | $1.02B | $986.57M | $997.10M | $972.93M | $936.43M | $969.92M | $985.85M | $999.34M | $1.02B | $1.01B | $1.04B | $919.71M | $647.91M | $490.12M | $353.27M | $353.39M | $329.31M | $259.26M |
| Account Payables | $9.06M | $7.09M | $4.55M | $2.43M | $5.25M | $3.12M | $3.25M | $7.30M | $3.21M | $3.05M | $4.96M | $20.19M | $2.60M | $3.60M | $12.08M | $3.15M | $3.31M | $5.27M | $2.69M | $4.56M |
| Short Term Debt | $4.17M | $- | $4.54M | $4.56M | $4.50M | $4.39M | $4.15M | $3.83M | $3.63M | $3.38M | $3.04M | $2.97M | $2.58M | $2.89M | $3.49M | $3.36M | $3.25M | $3.15M | $3.04M | $2.95M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $52.43M | $-4.39M | $-4.15M | $- | $- | $87.39M | $192.00M | $313.20M | $349.86M | $358.59M | $129.56M | $52.20M | $38.21M | $21.71M | $15.58M | $15.52M |
| Other Current Liabilities | $65.40M | $62.94M | $53.10M | $49.01M | $52.45M | $46.75M | $37.47M | $80.39M | $143.23M | $150.25M | $145.20M | $129.84M | $201.36M | $163.86M | $59.52M | $50.71M | $32.64M | $36.49M | $47.48M | $21.77M |
| Total Current Liabilities | $78.63M | $70.03M | $62.19M | $56.00M | $62.20M | $54.26M | $44.86M | $91.52M | $150.07M | $244.08M | $345.20M | $466.20M | $556.40M | $528.93M | $204.64M | $109.42M | $77.41M | $66.62M | $53.22M | $29.28M |
| Long Term Debt | $250.24M | $250.17M | $250.75M | $251.54M | $252.42M | $253.09M | $253.68M | $253.99M | $254.38M | $254.43M | $254.71M | $255.01M | $254.81M | $255.15M | $252.86M | $213.68M | $214.60M | $215.25M | $215.89M | $216.56M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $67.97M | $106.95M | $64.35M | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $60.58M | $60.37M | $60.53M | $60.54M | $60.41M | $60.66M | $60.69M | $60.69M | $384.00K | $251.00K | $295.00K | $276.00K | $5.66M | $79.00K | $81.00K | $2.90M | $2.57M | $2.23M | $1.91M | $1.60M |
| Total Non-Current Liabilities | $310.82M | $310.53M | $311.28M | $312.08M | $312.83M | $313.75M | $314.37M | $314.68M | $254.76M | $254.68M | $255.00M | $255.29M | $260.47M | $323.20M | $359.89M | $280.94M | $217.17M | $217.49M | $217.80M | $218.15M |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $389.46M | $380.56M | $373.47M | $368.08M | $375.02M | $368.02M | $359.23M | $406.19M | $404.84M | $498.76M | $600.20M | $721.49M | $816.87M | $852.13M | $564.53M | $390.36M | $294.58M | $284.11M | $271.02M | $247.43M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $125.00K | $131.00K | $131.00K | $131.00K | $130.00K | $129.00K | $129.00K | $128.00K | $128.00K | $127.00K | $126.00K | $126.00K | $123.00K | $120.00K | $114.00K | $114.00K | $110.00K | $110.00K | $109.00K | $88.00K |
| Retained Earnings | $-903.27M | $-910.33M | $-927.92M | $-939.30M | $-930.58M | $-930.80M | $-945.10M | $-948.53M | $-924.20M | $-991.93M | $-1.06B | $-1.18B | $-1.22B | $-1.32B | $-1.29B | $-1.29B | $-1.29B | $-1.28B | $-1.28B | $-1.23B |
| Accumulated Other Comprehensive Income Loss | $-4.72M | $514.00K | $-4.91M | $-4.37M | $-2.11M | $-5.96M | $-5.37M | $-4.20M | $-5.44M | $-9.26M | $-6.56M | $-4.16M | $-2.27M | $-1.53M | $-713.00K | $-1.13M | $273.00K | $-1.02M | $-2.10M | $-2.58M |
| Other Total Stockholders Equity | $1.50B | $1.59B | $1.58B | $1.56B | $1.55B | $1.54B | $1.53B | $1.52B | $1.51B | $1.50B | $1.48B | $1.48B | $1.44B | $1.39B | $1.37B | $1.39B | $1.35B | $1.35B | $1.34B | $1.25B |
| Total Stockholders Equity | $596.80M | $681.43M | $642.85M | $618.48M | $622.07M | $604.92M | $577.21M | $563.73M | $581.01M | $500.58M | $422.80M | $287.48M | $222.37M | $67.58M | $83.38M | $99.76M | $58.69M | $69.28M | $58.30M | $11.82M |
| Total Equity | $596.80M | $681.43M | $642.85M | $618.48M | $622.07M | $604.92M | $577.21M | $563.73M | $581.01M | $500.58M | $422.80M | $287.48M | $222.37M | $67.58M | $83.38M | $99.76M | $58.69M | $69.28M | $58.30M | $11.82M |
| Total Liabilities and Stockholders Equity | $986.26M | $1.06B | $1.02B | $986.57M | $997.10M | $972.93M | $936.43M | $969.92M | $985.85M | $999.34M | $1.02B | $1.01B | $1.04B | $919.71M | $647.91M | $490.12M | $353.27M | $353.39M | $329.31M | $259.26M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $986.26M | $1.06B | $1.02B | $986.57M | $997.10M | $972.93M | $936.43M | $969.92M | $985.85M | $999.34M | $1.02B | $1.01B | $1.04B | $919.71M | $647.91M | $490.12M | $353.27M | $353.39M | $329.31M | $259.26M |
| Total Investments | $617.95M | $644.66M | $623.38M | $591.78M | $592.02M | $565.90M | $454.70M | $477.61M | $422.39M | $387.91M | $269.08M | $323.80M | $109.76M | $167.80M | $216.20M | $153.62M | $265.93M | $144.47M | $140.22M | $91.63M |
| Total Debt | $254.42M | $250.17M | $255.28M | $256.10M | $256.91M | $253.09M | $257.83M | $253.99M | $258.01M | $257.81M | $257.75M | $257.98M | $257.38M | $258.04M | $256.35M | $217.04M | $217.85M | $218.40M | $218.93M | $219.51M |
| Net Debt | $158.53M | $130.84M | $142.78M | $124.07M | $106.64M | $98.58M | $31.01M | $79.64M | $56.01M | $59.24M | $8.65M | $78.56M | $-178.81M | $11.69M | $126.74M | $137.99M | $185.77M | $185.71M | $158.45M | $181.61M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $27.31M | $-6.39M | $293.16M | $76.71M | $-75.24M |
| Depreciation and Amortization | $8.05M | $7.28M | $6.67M | $7.01M | $9.34M |
| Deferred Income Tax | $- | $-5.24M | $61.77M | $56.69M | $-10.60M |
| Stock Based Compensation | $52.62M | $42.59M | $32.91M | $21.29M | $13.48M |
| Change in Working Capital | $-16.04M | $61.21M | $-298.42M | $172.22M | $-32.91M |
| Accounts Receivables | $-2.37M | $43.27M | $-15.70M | $-138.43M | $-45.32M |
| Inventory | $3.14M | $3.91M | $-32.40M | $-234.00K | $-22.36M |
| Accounts Payables | $3.90M | $1.95M | $691.00K | $-767.00K | $-3.45M |
| Other Working Capital | $-20.71M | $12.08M | $-251.01M | $311.65M | $38.21M |
| Other Non Cash Items | $-5.43M | $1.12M | $-33.38M | $1.61M | $3.68M |
| Net Cash Provided by Operating Activities | $66.51M | $100.56M | $62.72M | $335.53M | $-92.25M |
| Investments in Property Plant and Equipment | $-6.35M | $-4.10M | $-7.14M | $-9.48M | $-11.07M |
| Acquisitions Net | $- | $- | $1.00M | $1.00M | $7.00M |
| Purchases of Investments | $-524.06M | $-636.92M | $-632.31M | $-164.93M | $-201.79M |
| Sales Maturities of Investments | $512.38M | $486.10M | $322.45M | $187.63M | $179.47M |
| Other Investing Activities | $- | $1.00M | $- | $1.00M | $-149.00K |
| Net Cash Used for Investing Activities | $-18.04M | $-153.93M | $-316.00M | $14.22M | $-26.53M |
| Debt Repayment | $- | $- | $- | $29.63M | $- |
| Common Stock Issued | $- | $6.36M | $9.64M | $28.16M | $108.54M |
| Common Stock Repurchased | $-100.00M | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-2.02M | $1.39M | $19.52M | $-2.01M | $961.00K |
| Net Cash Used Provided by Financing Activities | $-102.02M | $1.39M | $19.52M | $55.78M | $109.50M |
| Effect of Forex Changes on Cash | $-862.00K | $324.00K | $-443.00K | $-1.43M | $1.49M |
| Net Change in Cash | $-54.40M | $-51.66M | $-234.20M | $404.10M | $-7.79M |
| Cash at End of Period | $96.15M | $150.56M | $202.21M | $436.41M | $32.31M |
| Cash at Beginning of Period | $150.56M | $202.21M | $436.41M | $32.31M | $40.10M |
| Operating Cash Flow | $66.51M | $100.56M | $62.72M | $335.53M | $-92.25M |
| Capital Expenditure | $-6.35M | $-4.10M | $-7.14M | $-9.48M | $-11.07M |
| Free Cash Flow | $60.16M | $96.46M | $55.58M | $326.05M | $-103.32M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $7.05M | $17.59M | $11.39M | $-8.72M | $219.00K | $14.29M | $3.43M | $-24.33M | $67.73M | $63.81M | $128.75M | $32.86M | $99.78M | $-28.43M | $4.47M | $891.00K | $-15.47M | $4.40M | $-51.58M | $-12.60M |
| Depreciation and Amortization | $2.07M | $2.05M | $1.98M | $1.95M | $1.96M | $1.87M | $1.79M | $1.66M | $1.45M | $3.13M | $357.00K | $1.73M | $1.72M | $1.76M | $1.77M | $1.76M | $1.76M | $1.75M | $1.88M | $3.95M |
| Deferred Income Tax | $- | $- | $- | $- | $8.81M | $-5.05M | $-3.77M | $- | $- | $- | $- | $- | $-16.56M | $44.19M | $3.28M | $25.77M | $395.00K | $-27.88M | $25.66M | $-8.77M |
| Stock Based Compensation | $13.00M | $13.08M | $13.52M | $13.01M | $11.31M | $10.69M | $10.56M | $10.03M | $8.73M | $8.61M | $7.93M | $7.65M | $6.16M | $5.38M | $5.02M | $4.72M | $3.52M | $4.10M | $4.09M | $1.78M |
| Change in Working Capital | $32.73M | $-11.54M | $-11.11M | $-26.12M | $6.65M | $7.64M | $17.16M | $29.76M | $-59.42M | $-27.05M | $-119.58M | $-92.37M | $30.34M | $43.57M | $93.85M | $4.47M | $-6.59M | $-10.59M | $-2.26M | $-13.47M |
| Accounts Receivables | $28.37M | $-12.65M | $-16.48M | $-1.62M | $-18.02M | $5.68M | $17.46M | $-5.12M | $26.73M | $43.12M | $-42.43M | $-5.12M | $-109.16M | $-157.88M | $-16.01M | $-61.33M | $8.36M | $-30.17M | $5.81M | $751.00K |
| Inventory | $-9.53M | $11.70M | $-656.00K | $-9.78M | $-5.53M | $3.08M | $4.61M | $1.75M | $23.36M | $-43.12M | $5.06M | $-17.70M | $3.37M | $19.15M | $-17.61M | $-5.16M | $-4.66M | $-4.64M | $-6.29M | $-6.77M |
| Accounts Payables | $1.88M | $2.59M | $2.07M | $-2.64M | $2.56M | $-461.00K | $-4.25M | $4.10M | $390.00K | $-2.02M | $-14.62M | $16.94M | $-222.00K | $-7.75M | $7.50M | $-295.00K | $-2.02M | $2.56M | $-1.90M | $-2.10M |
| Other Working Capital | $12.01M | $-13.18M | $3.95M | $-12.07M | $27.63M | $-659.00K | $-660.00K | $29.04M | $-109.89M | $-25.04M | $-67.59M | $-86.49M | $136.34M | $190.05M | $119.95M | $71.26M | $-8.28M | $21.66M | $120.00K | $-5.36M |
| Other Non Cash Items | $-1.84M | $-1.73M | $27.48M | $34.15M | $-15.18M | $1.69M | $-1.13M | $10.50M | $16.46M | $13.05M | $-813.00K | $-302.00K | $-938.00K | $-260.00K | $2.39M | $414.00K | $642.00K | $403.00K | $388.00K | $2.25M |
| Net Cash Provided by Operating Activities | $53.01M | $19.47M | $10.71M | $-16.68M | $13.77M | $31.13M | $28.05M | $27.62M | $34.95M | $61.56M | $16.65M | $-50.44M | $120.50M | $66.21M | $110.79M | $38.03M | $-15.74M | $-27.82M | $-21.82M | $-26.87M |
| Investments in Property Plant and Equipment | $-3.48M | $-1.35M | $-779.00K | $-749.00K | $-1.72M | $-347.00K | $-751.00K | $-1.28M | $-1.59M | $-1.28M | $-2.91M | $-1.36M | $-3.04M | $-3.63M | $-1.06M | $-1.75M | $-769.00K | $-265.00K | $-686.00K | $-9.35M |
| Acquisitions Net | $- | $- | $- | $- | $1.00M | $1.00M | $- | $- | $- | $- | $1.00M | $- | $- | $1.00M | $- | $- | $- | $- | $- | $7.00M |
| Purchases of Investments | $-33.02M | $-164.93M | $-175.44M | $-150.69M | $-152.88M | $-224.51M | $-74.23M | $-185.30M | $-117.63M | $-201.02M | $-63.28M | $-250.38M | $-1.00K | $1.00K | $-92.91M | $-72.02M | $-29.80M | $-68.80M | $-85.20M | $-17.98M |
| Sales Maturities of Investments | $59.86M | $150.81M | $147.45M | $154.26M | $134.36M | $117.78M | $99.70M | $134.25M | $86.25M | $83.25M | $117.70M | $35.25M | $57.98M | $48.30M | $30.23M | $51.13M | $40.92M | $64.15M | $36.50M | $37.90M |
| Other Investing Activities | $- | $- | $- | $- | $-1.00M | $- | $- | $- | $- | $- | $- | $- | $- | $1.00M | $- | $- | $3.99M | $2.86M | $- | $-7.00M |
| Net Cash Used for Investing Activities | $23.37M | $-15.46M | $-28.77M | $2.83M | $-20.24M | $-106.07M | $24.72M | $-52.33M | $-32.97M | $-119.05M | $52.50M | $-216.48M | $54.94M | $45.67M | $-63.75M | $-22.63M | $14.34M | $-2.05M | $-49.38M | $10.56M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $-2.96M | $419.00K | $2.54M | $486.00K | $3.48M | $1.38M | $1.02M | $9.64M | $8.06M | $1.03M | $10.29M | $8.24M | $6.66M | $-1.00K | $28.16M | $1.00K | $840.00K | $93.47M | $14.23M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-98.88M | $2.48M | $-1.42M | $-6.74M | $1.78M | $2.99M | $-294.00K | $-3.09M | $153.00K | $8.06M | $1.03M | $10.29M | $14.82M | $5.32M | $3.33M | $4.15M | $65.00K | $572.00K | $14.00K | $310.00K |
| Net Cash Used Provided by Financing Activities | $-98.88M | $2.48M | $-1.42M | $-4.20M | $1.78M | $2.99M | $-294.00K | $-3.09M | $153.00K | $8.06M | $1.03M | $10.29M | $14.82M | $5.32M | $3.33M | $32.30M | $66.00K | $1.41M | $93.48M | $14.54M |
| Effect of Forex Changes on Cash | $-960.00K | $363.00K | $-64.00K | $-201.00K | $479.00K | $-305.00K | $-1.00K | $151.00K | $1.31M | $-1.10M | $-523.00K | $-134.00K | $-418.00K | $-467.00K | $185.00K | $-731.00K | $731.00K | $675.00K | $313.00K | $-225.00K |
| Net Change in Cash | $-23.46M | $6.84M | $-19.53M | $-18.25M | $-4.22M | $-72.26M | $52.47M | $-27.65M | $3.45M | $-50.53M | $69.66M | $-256.77M | $189.83M | $116.74M | $50.56M | $46.97M | $-604.00K | $-27.79M | $22.59M | $-1.99M |
| Cash at End of Period | $96.15M | $119.61M | $112.50M | $132.03M | $150.56M | $154.78M | $227.03M | $174.56M | $202.21M | $198.76M | $249.29M | $179.63M | $436.41M | $246.57M | $129.84M | $79.28M | $32.31M | $32.91M | $60.70M | $38.11M |
| Cash at Beginning of Period | $119.61M | $112.50M | $132.03M | $150.28M | $154.78M | $227.03M | $174.56M | $202.21M | $198.76M | $249.29M | $179.63M | $436.41M | $246.57M | $129.84M | $79.28M | $32.31M | $32.91M | $60.70M | $38.11M | $40.10M |
| Operating Cash Flow | $53.01M | $19.47M | $10.71M | $-16.68M | $13.77M | $31.13M | $28.05M | $27.62M | $34.95M | $61.56M | $16.65M | $-50.44M | $120.50M | $66.21M | $110.79M | $38.03M | $-15.74M | $-27.82M | $-21.82M | $-26.87M |
| Capital Expenditure | $-3.48M | $-1.35M | $-779.00K | $-749.00K | $-1.72M | $-347.00K | $-751.00K | $-1.28M | $-1.59M | $-1.28M | $-2.91M | $-1.36M | $-3.04M | $-3.63M | $-1.06M | $-1.75M | $-769.00K | $-265.00K | $-686.00K | $-9.35M |
| Free Cash Flow | $49.53M | $18.12M | $9.93M | $-17.43M | $12.04M | $30.78M | $27.30M | $26.34M | $33.36M | $60.28M | $13.74M | $-51.80M | $117.46M | $62.58M | $109.72M | $36.28M | $-16.51M | $-28.09M | $-22.51M | $-36.22M |
Dynavax Technologies Dividends
Explore Dynavax Technologies's dividend history, including dividend yield, payout ratio, and historical payments.
Dynavax Technologies News
Read the latest news about Dynavax Technologies, including recent articles, headlines, and updates.
Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
EMERYVILLE, Calif. , April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2025 financial results on Tuesday, May 6, 2025, after the U.S. financial markets close.
Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.53% of the Company's outstanding shares, today announced that it has filed a definitive proxy statement in connection with its nomination of four highly qualified candidates for election to the Company's Board of Directors (the “B.
Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders
Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy andMeaningful Board Refreshment Underscores Deep Track's Value Destructive, Short-Term Focus and Unnecessary Proxy Contest EMERYVILLE, Calif. , April 17, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has filed definitive proxy materials with the Securities and Exchange Commission ("SEC") in connection with its upcoming Annual Meeting of Stockholders scheduled to be held on June 11, 2025.
Deep Track Capital Comments on Dynavax Technologies' Rejection of Most Recent Settlement Offer
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”) is one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.34% of the Company's outstanding shares. Today Deep Track commented on the Company's disclosure that the Board of Directors (the “Board”) has rejected a settlement proposal in connection with its nomination of four highly qualif.
Dynavax Files Preliminary Proxy Statement
Dynavax's Board is Overseeing Record Operational and Financial Performance Outlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a Resolution EMERYVILLE, Calif. , April 3, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today filed its preliminary proxy materials with the Securities and Exchange Commission ("SEC") in connection with its upcoming Annual Meeting of Stockholders ("the 2025 Annual Meeting").
Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase
Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure $225 million of convertible notes due in 2030 issued, including an exchange for the retirement of ~$185 million of existing convertible notes due in 2026 and ~$40 million of new money Dynavax repurchased ~$8 million of the Company's common stock in connection with this transaction EMERYVILLE, Calif. , March 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, has entered into privately negotiated exchange and subscription agreements (the "Exchange Agreements") with a limited number of holders of its outstanding 2.50% Convertible Senior Notes due 2026 (the "2026 Notes") and one new investor, pursuant to which the Company will issue $225 million aggregate principal amount of 2.0% Convertible Senior Notes due 2030 (the "New Notes") comprised of (i) an exchange for the retirement of approximately $185 million in aggregate principal amount of existing 2026 Notes, and (ii) approximately $40 million of New Notes issued to existing holders and one new investor (the "Transactions").
Dynavax Technologies: A Post-Earnings Assessment With Growing Market Share
Dynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its superior efficacy and compliance compared to previous hepatitis B vaccines. Heplisav-B should eventually garner 60% of a market that is predicted to grow to $900 million in the U.S. by 2030.
Dynavax to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif. , Feb. 25, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 1:10 p.m.
Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 81.92%: Read This Before Placing a Bet
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 81.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer Conference Call Participants Matt Phipps - William Blair Roy Buchanan - Citizens Jonathan Miller - Evercore ISI Phil Nadeau - TD Cowen Ed White - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Dynavax Technologies' Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance
HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in Phase 1/2 shingles trial expected in Q3 2025 Plan to initiate Phase 2 trial for plague vaccine in Q3 2025 Expect completion of $200 million share repurchase program in 2025 Conference call today at 4:30 p.m. ET/1:30 p.m.
Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy
Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif. , Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a statement underscoring continued execution momentum and commitment to driving long-term stockholder value.
Exclusive: Investor Deep Track launches proxy fight at Dynavax, nominates 4 directors
Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies , pressing for new directors to prioritize the development of the company's hepatitis B vaccine instead of pursuing new acquisitions.
Dynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on February 20, 2025
EMERYVILLE, Calif. , Feb. 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the U.S. financial markets close.
Wall Street Analysts Believe Dynavax Technologies (DVAX) Could Rally 93.2%: Here's is How to Trade
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 93.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Dynavax Advances Board Refreshment Program
Appoints Emilio Emini and Lauren Silvernail to Board of Directors; Two Directors to Step Down at 2025 Annual Meeting Intends to Seek Stockholder Approval for Declassification of Board at 2025 Annual Meeting EMERYVILLE, Calif. , Jan. 27, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) (the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced the following changes to its Board of Directors as part of its ongoing refreshment program: Emilio Emini, Ph.D.
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
Preliminary 2024 HEPLISAV-B® net product revenue grew 26% year-over-year to approximately $268 million Enrollment completed in Phase 1/2 shingles trial; top line results expected in Q3 2025 New $30 million contract with U.S. Department of Defense to advance plague vaccine program Cash, cash equivalents and marketable securities were approximately $714 million as of December 31, 2024 EMERYVILLE, Calif. , Jan. 13, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced preliminary, unaudited financial highlights for the fourth quarter and full year ended December 31, 2024.
Does Dynavax Technologies (DVAX) Have the Potential to Rally 93.52% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 93.5% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
EMERYVILLE, Calif. , Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 2:35 p.m.
Dynavax Technologies: What The Stock Buyback Means. What It Doesn't
Today, we revisit Dynavax Technologies Corporation, whose shares have moved up nicely after the company announced a significant buyback authorization. In addition, DVAX's flagship product Heplisav-B continues to increase market share consistently in a growing market. The company has also moved towards profitability and analyst firms have price targets significantly above the current trading level of the stock, even after its recent rally.
Wall Street Analysts Predict an 88.32% Upside in Dynavax Technologies (DVAX): Here's What You Should Know
The consensus price target hints at an 88.3% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Dynavax Announces $100 Million Accelerated Share Repurchase Program
EMERYVILLE, Calif. , Nov. 11, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has entered into an Accelerated Share Repurchase transaction ("ASR") under an agreement with Goldman Sachs & Co. LLC to repurchase $100 million of the Company's common stock.
Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates
HEPLISAV-B ® quarterly net product revenue of $79.3 million, representing 27% year-over-year growth Hepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total market share Expect positive net income in 2024, achieving full year profitability Strengthened cash position to $764 million in Q3'24 $ 200 million share repurchase program announced as part of balanced capital allocation strategy Conference call today at 4:30 p.m. ET/1:30 p.m.
Dynavax Announces $200 Million Share Repurchase Program
EMERYVILLE, Calif. , Nov. 7, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced its Board of Directors has authorized the repurchase of up to $200 million of the Company's common stock.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for DVAX.